Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNP-2301
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DHNP-2301 is a small molecule drug candidate being developed by Daehan Nupharm for the treatment of gastroesophageal reflux disease (GERD). Currently in the formulation research stage, it is classified as an incrementally modified drug (IMD) or a new drug candidate within the developer's pipeline. The candidate is intended to manage gastric acid secretion to alleviate symptoms associated with GERD, though its specific molecular target and chemical structure have not been publicly disclosed. As an IMD, it likely represents an optimized formulation or a new salt of an existing therapeutic agent designed to improve clinical outcomes or patient adherence.
Beyond the preview
Go deeper on DHNP-2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNP-2301.